DK1963307T3 - 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propion- eller propensyre som H1- og H3-receptorantagonister til behandling af inflammatoriske og/eller allergiske lidelser - Google Patents

3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propion- eller propensyre som H1- og H3-receptorantagonister til behandling af inflammatoriske og/eller allergiske lidelser

Info

Publication number
DK1963307T3
DK1963307T3 DK06841477.0T DK06841477T DK1963307T3 DK 1963307 T3 DK1963307 T3 DK 1963307T3 DK 06841477 T DK06841477 T DK 06841477T DK 1963307 T3 DK1963307 T3 DK 1963307T3
Authority
DK
Denmark
Prior art keywords
piperidinyl
naphthalenyl
oxy
propionic
carbonyl
Prior art date
Application number
DK06841477.0T
Other languages
English (en)
Inventor
Simon Teanby Hodgson
Panayiotis Alexandrou Procopiou
Brugarolas Maria Victoria Vinader
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0525897A external-priority patent/GB0525897D0/en
Priority claimed from GB0623217A external-priority patent/GB0623217D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1963307T3 publication Critical patent/DK1963307T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK06841477.0T 2005-12-20 2006-12-19 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propion- eller propensyre som H1- og H3-receptorantagonister til behandling af inflammatoriske og/eller allergiske lidelser DK1963307T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0525897A GB0525897D0 (en) 2005-12-20 2005-12-20 Compounds
GB0623217A GB0623217D0 (en) 2006-11-21 2006-11-21 Compounds
PCT/EP2006/069943 WO2007071691A1 (en) 2005-12-20 2006-12-19 3- (4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] 0xy} phenyl) -1-piperidinyl] carbonyl }-1-naphthalenyl) propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders

Publications (1)

Publication Number Publication Date
DK1963307T3 true DK1963307T3 (da) 2010-04-06

Family

ID=37845266

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06841477.0T DK1963307T3 (da) 2005-12-20 2006-12-19 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propion- eller propensyre som H1- og H3-receptorantagonister til behandling af inflammatoriske og/eller allergiske lidelser

Country Status (24)

Country Link
US (1) US7989629B2 (da)
EP (2) EP1963307B1 (da)
JP (2) JP4445570B2 (da)
KR (1) KR20080087102A (da)
AR (1) AR058109A1 (da)
AT (1) ATE449769T1 (da)
AU (1) AU2006328512B2 (da)
BR (1) BRPI0620218A2 (da)
CA (1) CA2634391A1 (da)
CR (1) CR10102A (da)
CY (1) CY1110601T1 (da)
DE (1) DE602006010737D1 (da)
DK (1) DK1963307T3 (da)
EA (1) EA014354B1 (da)
ES (1) ES2337187T3 (da)
IL (1) IL191967A0 (da)
MA (1) MA30373B1 (da)
NO (1) NO20082695L (da)
PE (1) PE20071068A1 (da)
PL (1) PL1963307T3 (da)
PT (1) PT1963307E (da)
SI (1) SI1963307T1 (da)
TW (1) TW200730498A (da)
WO (1) WO2007071691A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US20120149731A1 (en) 2009-06-29 2012-06-14 Glaxo Group Limited New medical use
JP4785963B2 (ja) 2009-10-09 2011-10-05 キヤノン株式会社 固体撮像装置
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
KR101640756B1 (ko) 2014-10-28 2016-07-19 이종찬 전동 드릴 장착용 내시경 캡
WO2019169082A1 (en) * 2018-03-01 2019-09-06 Ferox Therapeutics Llc Methods of preventing and treating hypoglycemia in type 1 and type 2 diabetes patients
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
EP0957087B1 (en) 1994-06-15 2002-12-04 The Wellcome Foundation Limited Intermediates useful in the preparation of enzyme inhibitors
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
WO1999016766A1 (en) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
AU4501800A (en) 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
EP1467982B8 (en) 2002-01-14 2007-04-11 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
JP4324480B2 (ja) 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004005229A1 (en) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulators of the glucocorticoid receptor
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
AU2003270783C1 (en) 2002-09-20 2010-05-20 Merck Sharp & Dohme Corp. Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2003298094A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Medicinal arylethanolamine compounds
JP2006512404A (ja) * 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
DE60320007T2 (de) 2002-10-28 2009-06-18 Glaxo Group Ltd., Greenford Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US7465795B2 (en) 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
CA2649029A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited 2-substituted 4-benzylphthalazinone derivatives as histamine h1 and h3 antagonists

Also Published As

Publication number Publication date
BRPI0620218A2 (pt) 2011-11-01
US7989629B2 (en) 2011-08-02
PT1963307E (pt) 2010-03-03
ATE449769T1 (de) 2009-12-15
JP4445570B2 (ja) 2010-04-07
CA2634391A1 (en) 2007-06-28
KR20080087102A (ko) 2008-09-30
EP1963307B1 (en) 2009-11-25
EA014354B1 (ru) 2010-10-29
CR10102A (es) 2008-09-22
PL1963307T3 (pl) 2010-05-31
JP2009235087A (ja) 2009-10-15
WO2007071691A1 (en) 2007-06-28
US20080312280A1 (en) 2008-12-18
PE20071068A1 (es) 2007-12-13
MA30373B1 (fr) 2009-05-04
EP2157087A1 (en) 2010-02-24
NO20082695L (no) 2008-09-16
AU2006328512A1 (en) 2007-06-28
EP1963307A1 (en) 2008-09-03
DE602006010737D1 (de) 2010-01-07
HK1120265A1 (en) 2009-03-27
JP2009520001A (ja) 2009-05-21
TW200730498A (en) 2007-08-16
AR058109A1 (es) 2008-01-23
AU2006328512B2 (en) 2011-06-23
EA200801342A1 (ru) 2008-12-30
CY1110601T1 (el) 2015-04-29
IL191967A0 (en) 2008-12-29
ES2337187T3 (es) 2010-04-21
SI1963307T1 (sl) 2010-03-31

Similar Documents

Publication Publication Date Title
LTPA2020525I1 (lt) Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
ZA200702392B (en) New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carbo xylic acid for the treatment of hyper-proliferative disorders
ATE516272T1 (de) 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
IL191967A0 (en) 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl) propyl]oxy}phenyl)-1-piperidinyl]carbonyl]-1-naphthalenyl)propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
CY2016017I2 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
IL192241A (en) A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK1968949T3 (da) Forbedret fremgangsmåde til fremstilling af salte af 4-(benzimidazolylmethylamino)-benzamider
DK2051976T3 (da) 4-[5-Methoxy-6-(2-methyl-6[1,2,4)triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidin-1-carboxylsyre-isopropylester som modulator af metabolisme og behandling af lidelser beslægtet dermed
DE602007010303D1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
DK1907373T3 (da) Fremgangsmåder til fremstillingen af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dionforbindelser
DK2059513T3 (da) Fremgangsmåde til fremstillingen af 1,2,4-oxadiazolbenzoesyrer
DK2029524T3 (da) Fremgangsmåde til fremstilling af 2-[4-(3- og 2-fluorbenzyloxy)benzyl-amino]propanamider
CL2007002930A1 (es) Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
ATE538114T1 (de) 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK1959988T3 (da) Anvendelse af bovint lactoferrin til behandling af destruktiv inflammation af slimhinder
DK1838697T3 (da) Fremgangsmåder til at fremstille 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)-piperidin-1-carboxylsyre-derivater og relaterede forbindelser
DK1734959T3 (da) Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter